logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
PE/iFluor® 700 Anti-human CD7 Antibody
HIT7
HIT7 is an anti-human monoclonal antibody that recognizes the CD7 antigen. CD7 (also known as gp40) is a 40 kD single-pass type I membrane protein that is located on the surface of cells like NK cells, stem cells and T cells. CD7 has been closely linked to essential biological processes such as immune response, particularly adaptive immune response. Furthermore, it is involved with important cellular pathways, namely, the transmembrane receptor protein tyrosine kinase signaling pathway. From a research standpoint, it is of biological interest due to its association with vital macromolecules/ligands like PI3-Kinase. CD7 is a fairly uncommon antibody target, with a little more than 3600 publications in the last decade. Even still, CD7 is commonly used in flow cytometry applications as a phenotypic marker for differentiation of cell types, especially in the study of immunology and costimulatory molecules. This antibody was purified through affinity chromatography and conjugated to PE/iFluor® 700 (ex/em = 566/708 nm). It is compatible with the 561 nm laser and 695/40 nm bandpass filter (for example, as in the Agilent Technologies NovoCyte).
product image
product image
CatalogSize
Price
Quantity
100701X025 tests
Price
100701X1100 tests
Price
100701X2500 tests
Price
 
Antibody properties

Other namesgp40; TP41
CloneHIT7
Hostmouse
Isotypemouse IgG1
Reactivityhuman
Spectral properties

Absorbance (nm)566
Extinction coefficient (cm -1 M -1)
1960000
Excitation (nm)565
Emission (nm)708
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on October 10, 2025